ClinicalTrials.gg
CompletedNCT03158220Updated Nov 21, 2019Results posted

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

A Phase 3 interventional study of V503 in Cervical Cancer, Vulvar Cancer and Vaginal Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 24 sites in 6 countries. Open to female participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,212
Allocation
Non-randomized
Ages
16 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms — 6 open to participants now, 8 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Uterine Cervical Neoplasms.

Enrollment
7th of 14
1,212 · median 1,206
Started
2017
with 1 other
Phase 3
9 of 14
2 open now
Registered
5th of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 3, and was the 5th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

6 of the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 16 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4 weeks postdose 3 are non-inferior in adult women as compared with GMTs in young adult women.

03

Conditions studied

  • Cervical Cancer
  • Vulvar Cancer
  • Vaginal Cancer
  • Genital Warts
  • Human Papillomavirus Infection
04

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • good physical health

Exclusion criteria

Exclusion Criteria:

  • history of an abnormal Pap (Papanicolaou) test or abnormal cervical results
  • history of HPV-related condition
  • history of known prior vaccination with an HPV vaccine
  • pregnant
  • user of recreational or illicit drugs
  • history of severe allergic reaction, including known allergy to any vaccine component
  • history of certain medications or is currently taking or has taken certain medications (details will be discussed at the time of consent)
  • has thrombocytopenia or other coagulation disorder
  • concurrently enrolled in a clinical study of agent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,212 participants (actual)

Study arms

  • Experimental
    Adult Women 27- to 45-years Old

    Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.

    Biological: V503

  • Active comparator
    Young Adult Women 16- to 26-years Old

    Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.

    Biological: V503

Interventions

  • BiologicalV503

    V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6

    Also known as: GARDASIL®9 (HPV 9-valent vaccine [recombinant, adsorbed]); HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

06

What researchers measure

Primary outcomes

  1. Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type

    Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL). Statistical comparisons between arms was performed for the HPV types considered oncogenic (HPV Types 16/18/31/33/45/52/58).

    Time frame: 4 weeks post vaccination 3 (Month 7)

Secondary outcomes

  1. Percentage of Participants That Experienced at Least 1 Adverse Event (AE)

    An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants with 1 or more AEs was assessed.

    Time frame: Up to 1 month post vaccination 3 (up to 7 months)

  2. Percentage of Participants Who Had Study Vaccine Discontinued Due to Adverse Event.

    An adverse event is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants who discontinued the study vaccine due to an adverse event regardless of study completion status was assessed.

    Time frame: Up to 1 month post vaccination 3 (up to 7 months)

  3. Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event

    Participants were asked to record any injection-site reactions prompted in the Vaccination Report Card, i.e., injection-site tenderness, swelling, or redness, occurring after each study vaccination (solicited injection-site reactions). The percentage of participants with 1 or more solicited injection-site AE was assessed.

    Time frame: Up to 5 days post any vaccination

  4. Percentage of Participants That Reported at Least 1 Systemic Adverse Event

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs. The percentage of participants that reported at least 1 systemic AE was assessed

    Time frame: Up to 15 days post any vaccination

  5. Percentage of Participants With Elevated Temperature (Fever)

    Participants were asked to record oral body temperature in the Vaccination Report Card. The percentage of participants with elevated temperature (≥37.8°C or 100.0°F) was assessed.

    Time frame: Up to 5 days post any vaccination

  6. Percentage of Participants Who Seroconverted to Each of the Anti-HPV Types

    Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. The percentage of participants who were seronegative on Day 1 and have anti-HPV titer greater or equal to the type-specific serostatus cutoff at 4 weeks postdose 3 was assessed.

    Time frame: 4 weeks post vaccination 3 (Month 7)

07

Results

Posted Nov 21, 2019

Participant flow

Participant flow — Overall Study
MilestoneWomen 16-26 Years of AgeWomen 27-45 Years of Age
Started570642
Vaccination 1570640
Vaccination 2563635
Vaccination 3556629
Completed553626
Not completed1716
Withdrew: Screen failure01
Withdrew: Withdrawal by subject89
Withdrew: Status unknown01
Withdrew: Lost to follow-up85
Withdrew: Physician decision10

Outcome measures

PrimaryAnti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type

Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL). Statistical comparisons between arms was performed for the HPV types considered oncogenic (HPV Types 16/18/31/33/45/52/58).

Time frame:
4 weeks post vaccination 3 (Month 7)
Reported as:
Geometric mean · mMU/mL
Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type
mMU/mLWomen 16-26 Years of AgeWomen 27-45 Years of Age
Anti-HPV 6787.8 (732.5 to 847.2)638.4 (594.9 to 685.0)
Anti-HPV 11598.7 (558.7 to 641.6)453.5 (424.1 to 485.0)
Anti-HPV 163075.8 (2863.4 to 3303.9)2147.5 (2001.1 to 2304.5)
Anti-HPV 18744.5 (685.0 to 809.1)532.1 (491.8 to 575.7)
Anti-HPV 31596.1 (551.1 to 644.9)395.7 (367.0 to 426.6)
Anti-HPV 33354.5 (331.7 to 378.9)259.0 (242.9 to 276.1)
Anti-HPV 45214.9 (197.7 to 233.7)145.6 (134.4 to 157.7)
Anti-HPV 52346.5 (324.0 to 370.5)244.7 (229.4 to 261.0)
Anti-HPV 58428.0 (399.4 to 458.6)296.4 (277.1 to 317.0)
Statistical analysis
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · ANOVA · p = < 0.001 (Analysis of variance (ANOVA) model with response of log individual titers and a fixed effect for age groups.) · Fold difference: 0.70 · 95% CI 0.63 to 0.77Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · ANOVA · p = < 0.001 (Analysis of variance (ANOVA) model with response of log individual titers and a fixed effect for age groups.) · Fold difference: 0.71 · 95% CI 0.64 to 0.80Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · ANOVA · p = < 0.001 (ANOVA model with response of log individual titers and a fixed effect for age groups.) · Fold difference: 0.66 · 95% CI 0.60 to 0.74Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · ANOVA · p = < 0.001 (ANOVA model with response of log individual titers and a fixed effect for age groups.) · Fold difference: 0.73 · 95% CI 0.67 to 0.80Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · ANOVA · p = < 0.001 (ANOVA model with response of log individual titers and a fixed effect for age groups.) · Fold difference: 0.68 · 95% CI 0.60 to 0.76Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · ANOVA · p = < 0.001 (ANOVA model with response of log individual titers and a fixed effect for age groups.) · Fold difference: 0.71 · 95% CI 0.64 to 0.78Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · ANOVA · p = < 0.001 (ANOVA model with response of log individual titers and a fixed effect for age groups.) · Fold difference: 0.69 · 95% CI 0.63 to 0.76Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds
SecondaryPercentage of Participants That Experienced at Least 1 Adverse Event (AE)

An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants with 1 or more AEs was assessed.

Time frame:
Up to 1 month post vaccination 3 (up to 7 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants That Experienced at Least 1 Adverse Event (AE)
Percentage of ParticipantsWomen 16-26 Years of AgeWomen 27-45 Years of Age
Percentage of Participants That Experienced at Least 1 Adverse Event (AE)92.892.5
SecondaryPercentage of Participants Who Had Study Vaccine Discontinued Due to Adverse Event.

An adverse event is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants who discontinued the study vaccine due to an adverse event regardless of study completion status was assessed.

Time frame:
Up to 1 month post vaccination 3 (up to 7 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Study Vaccine Discontinued Due to Adverse Event.
Percentage of ParticipantsWomen 16-26 Years of AgeWomen 27-45 Years of Age
Percentage of Participants Who Had Study Vaccine Discontinued Due to Adverse Event.0.00.2
SecondaryPercentage of Participants With at Least 1 Solicited Injection-site Adverse Event

Participants were asked to record any injection-site reactions prompted in the Vaccination Report Card, i.e., injection-site tenderness, swelling, or redness, occurring after each study vaccination (solicited injection-site reactions). The percentage of participants with 1 or more solicited injection-site AE was assessed.

Time frame:
Up to 5 days post any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event
Percentage of ParticipantsWomen 16-26 Years of AgeWomen 27-45 Years of Age
Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event87.284.7
Statistical analysis
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · Miettinen & Nurminen · p = 0.212 · Difference in percentages: -2.5 · 95% CI -6.4 to 1.4Difference in percentages calculated as % Women 27-45 Years of Age minus % Women 16-26 Years of Age.
SecondaryPercentage of Participants That Reported at Least 1 Systemic Adverse Event

An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs. The percentage of participants that reported at least 1 systemic AE was assessed

Time frame:
Up to 15 days post any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants That Reported at Least 1 Systemic Adverse Event
Percentage of ParticipantsWomen 16-26 Years of AgeWomen 27-45 Years of Age
Percentage of Participants That Reported at Least 1 Systemic Adverse Event66.364.4
Statistical analysis
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · Difference in percentages: -1.9 · 95% CI -7.3 to 3.4Difference in percentages calculated as % Women 27-45 Years of Age minus % Women 16-26 Years of Age.
SecondaryPercentage of Participants With Elevated Temperature (Fever)

Participants were asked to record oral body temperature in the Vaccination Report Card. The percentage of participants with elevated temperature (≥37.8°C or 100.0°F) was assessed.

Time frame:
Up to 5 days post any vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Elevated Temperature (Fever)
Percentage of ParticipantsWomen 16-26 Years of AgeWomen 27-45 Years of Age
Percentage of Participants With Elevated Temperature (Fever)3.52.5
Statistical analysis
  • Women 16-26 Years of Age vs Women 27-45 Years of Age · Miettinen & Nurminen · p = 0.300 · Difference in percentages: -1.0 · 95% CI -3.1 to 0.9Difference in percentages calculated as % Women 27-45 Years of Age minus % Women 16-26 Years of Age.
SecondaryPercentage of Participants Who Seroconverted to Each of the Anti-HPV Types

Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. The percentage of participants who were seronegative on Day 1 and have anti-HPV titer greater or equal to the type-specific serostatus cutoff at 4 weeks postdose 3 was assessed.

Time frame:
4 weeks post vaccination 3 (Month 7)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Seroconverted to Each of the Anti-HPV Types
Percentage of ParticipantsWomen 16-26 Years of AgeWomen 27-45 Years of Age
Anti HPV 699.8 (98.7 to 100.0)100.0 (99.2 to 100.0)
Anti HPV 11100.0 (99.1 to 100.0)99.8 (98.8 to 100.0)
Anti HPV 16100.0 (99.2 to 100.0)100.0 (99.2 to 100.0)
Anti HPV 18100.0 (99.1 to 100.0)99.6 (98.5 to 99.9)
Anti HPV 31100.0 (99.2 to 100.0)99.8 (98.9 to 100.0)
Anti HPV 33100.0 (99.2 to 100.0)99.8 (98.9 to 100.0)
Anti HPV 4599.6 (98.5 to 99.9)99.2 (98.0 to 99.8)
Anti HPV 52100.0 (99.2 to 100.0)100.0 (99.3 to 100.0)
Anti HPV 58100.0 (99.2 to 100.0)99.8 (98.8 to 100.0)

Adverse events

Collected over Up to 1 month post vaccination 3 (up to 7 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Women 16-26 Years of Age0/570 (0%)6/570 (1.1%)518/570 (90.9%)
Women 27-45 Years of Age0/640 (0%)8/640 (1.3%)574/640 (89.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventWomen 16-26 Years of AgeWomen 27-45 Years of Age
Abortion inducedSurgical and medical procedures2/5701/640
Abdominal painGastrointestinal disorders1/5700/640
Rectal abscessInfections and infestations1/5700/640
TonsillitisInfections and infestations1/5701/640
Head injuryInjury, poisoning and procedural complications1/5700/640
PneumoniaInfections and infestations0/5701/640
Cervical vertebral fractureInjury, poisoning and procedural complications0/5701/640
Ligament injuryInjury, poisoning and procedural complications0/5701/640
Meniscus injuryInjury, poisoning and procedural complications0/5701/640
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/5701/640
Most frequent other events
Most frequent other events
EventWomen 16-26 Years of AgeWomen 27-45 Years of Age
Injection site painGeneral disorders492/570532/640
HeadacheNervous system disorders185/570200/640
Injection site swellingGeneral disorders137/570152/640
Injection site erythemaGeneral disorders112/570111/640
NasopharyngitisInfections and infestations53/57056/640
DysmenorrhoeaReproductive system and breast disorders51/57022/640
Oropharyngeal painRespiratory, thoracic and mediastinal disorders40/57046/640
PyrexiaGeneral disorders36/57028/640
NauseaGastrointestinal disorders31/57027/640
FatigueGeneral disorders28/57033/640

Baseline characteristics

Age, Continuous
Age, Continuous(years)Women 16-26 Years of AgeWomen 27-45 Years of AgeTotal
Mean21.6 ± 2.835.8 ± 5.529.1 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Women 16-26 Years of AgeWomen 27-45 Years of AgeTotal
Female5706421212
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Women 16-26 Years of AgeWomen 27-45 Years of AgeTotal
Hispanic21728
Not Hispanic5486341182
Unknown112
Race
Race(Participants)Women 16-26 Years of AgeWomen 27-45 Years of AgeTotal
American Indian or Alaska Native213
Asian171027
Black or African American538
Multiple718
White5396271166
08

Study locations

24 sites
  • Universitatsklinik fuer Frauenheilkunde und Geburtshilfe ( Site 0002)
    Graz, Austria
  • Klin. Abtlg. fuer Gynaekologie und Geburtshilfe ( Site 0001)
    Wien, Austria
  • Universitair Ziekenhuis Antwerpen ( Site 0007)
    Edegem, Belgium
  • Universitair Ziekenhuis Gent ( Site 0006)
    Gent, Belgium
  • Universitair Ziekenhuis Gasthuisberg ( Site 0005)
    Leuven, Belgium
  • University of Antwerp ( Site 0004)
    Wilrijk, Belgium
  • HUS Katiloopiston sairaala ( Site 0009)
    Helsinki, Finland
  • Ita-Helsingin Rokotetutkimuskeskus ( Site 0011)
    Helsinki, Finland
  • Porin Rokotetutkimusklinikka ( Site 0012)
    Pori, Finland
  • Tampereen yliopisto - Tampereen rokotetutkimusklinikka ( Site 0010)
    Tampere, Finland
  • Turun rokotetutkimusklinikka ( Site 0037)
    Turku, Finland
  • Universitaetsmedizin Berlin Charite ( Site 0016)
    Berlin, Germany
  • Universitaetsklinikum Duesseldorf ( Site 0014)
    Dusseldorf, Germany
  • Praxis Dr. Peters ( Site 0015)
    Hamburg, Germany
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0017)
    Hamburg, Germany
  • Universitaetsklinikum Tuebingen ( Site 0013)
    Tuebingen, Germany
  • Istituto Nazionale dei tumori ( Site 0020)
    Milano, Milan, Italy
  • Ospedale San Raffaele ( Site 0022)
    Milano, Italy
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello ( Site 0023)
    Palermo, Italy
  • CAP Centelles ( Site 0027)
    Centelles, Barcelona, Spain
  • Complejo Hospitalario de Torrecardenas ( Site 0030)
    Almeria, Spain
  • Institut Catala Oncologia de Bellvitge - ICO ( Site 0026)
    Hospitalet de Llobregat, Spain
  • Hospital Sanitas La Moraleja ( Site 0031)
    Madrid, Spain
  • Hospital Universitario Infanta Leonor ( Site 0028)
    Madrid, Spain
09

References and documents

Publications

  • Joura EA, Ulied A, Vandermeulen C, Rua Figueroa M, Seppa I, Hernandez Aguado JJ, Ahonen A, Reich O, Virta M, Perino A, Peris Tuser M, Peters K, Origoni M, Raspagliesi F, Tjalma WAA, Tummers P, Woelber L, Nieminen P, van Damme P, Sehouli J, Fiol Ruiz G, Brucker S, Fehm T, Cheon K, Rawat S, Luxembourg A, Wittke F. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. Vaccine. 2021 May 12;39(20):2800-2809. doi: 10.1016/j.vaccine.2021.01.074. Epub 2021 Mar 3. PubMed 33676783 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2018, 13 months.

Results were first posted in Nov 2019, 1 year after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 13 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2017
First posted
May 18, 2017
StartActual
Sep 20, 2017
Primary completionActual
Nov 19, 2018
CompletionActual
Nov 19, 2018
Results first posted
Nov 21, 2019
Last update
Nov 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03158220
Responsible party
Sponsor
First posted
May 18, 2017
Start date
Sep 20, 2017
Primary completion
Nov 19, 2018
Completion
Nov 19, 2018
Results posted
Nov 21, 2019
Last update
Nov 21, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion